NASDAQ : KALV
KalVista Pharmaceuticals, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 27 USD (At close: Jun 10, 2026) · Market cap 1.44B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
KalVista Pharmaceuticals, Inc. (KALV) reported revenue of 114.48M USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2025 | FY2024 | FYNone | FY2023 | |
|---|---|---|---|---|---|---|
| Revenue | 114.48M | 73.62M | ||||
| Cost of Revenue | 56.02M | 54.68M | 71.71M | 86.17M | 80.28M | |
| Gross Profit | 58.47M | 18.94M | -71.71M | -86.17M | -80.28M | |
| Selling, General & Admin | 198.47M | 185.21M | 116.29M | 54.28M | 30.59M | |
| Operating Expenses | 198.47M | 185.21M | 116.29M | 54.28M | 30.59M | |
| Operating Income | -140.00M | -166.27M | -188.00M | -140.44M | -110.87M | |
| Interest Expense | -21.99M | -19.34M | -5.79M | |||
| Interest & Investment Income | 9.50M | 8.68M | 6.43M | 3.90M | 2.23M | |
| Currency Exchange Gain (Loss) | -2.66M | 45.00K | 2.48M | 138.00K | 90.00K | |
| Other Non Operating Income (Expenses) | 13.64M | 10.99M | 3.25M | 8.44M | 15.78M | |
| EBT Excluding Unusual Items | -141.52M | -165.89M | -181.61M | -127.97M | -92.77M | |
| Gain (Loss) on Sale of Investments | 1.57M | 1.84M | 1.56M | 1.32M | -139.00K | |
| Asset Writedown | -1.78M | -1.78M | ||||
| Pretax Income | -141.73M | -165.84M | -180.05M | -126.64M | -92.91M | |
| Income Tax Expense | -5.80M | -1.55M | 3.39M | |||
| Net Income | -135.94M | -164.29M | -183.44M | -126.64M | -92.91M | |
| Net Income to Common | -135.94M | -164.29M | -183.44M | -126.64M | -92.91M | |
| Shares Outstanding (Basic) | 54.25M | 53.87M | 49.65M | 36.79M | 27.89M | |
| Shares Outstanding (Diluted) | 54.25M | 53.87M | 49.65M | 36.79M | 27.89M | |
| EPS (Basic) | -2.51 | -3.05 | -3.69 | -3.44 | -3.33 | |
| EPS (Diluted) | -2.51 | -3.05 | -3.69 | -3.44 | -3.33 | |
| Free Cash Flow | -91.71M | -124.99M | -153.34M | -89.27M | -76.46M | |
| Free Cash Flow Per Share | -1.69 | -2.32 | -3.09 | -2.43 | -2.74 | |
| Gross Margin | 51.07% | 25.73% | ||||
| Operating Margin | -122.30% | -225.86% | ||||
| Profit Margin | -118.74% | -223.16% | ||||
| Free Cash Flow Margin | -80.11% | -169.79% | ||||
| EBITDA | -138.45M | -164.82M | -187.05M | -139.63M | -110.15M | |
| EBITDA Margin | -120.93% | -223.88% | ||||
| D&A For EBITDA | 1.56M | 1.45M | 941.00K | 816.00K | 718.00K | |
| EBIT | -140.00M | -166.27M | -188.00M | -140.44M | -110.87M | |
| EBIT Margin | -122.30% | -225.86% |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2025 | FY2024 | FYNone | FY2023 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 213.77M | 229.34M | 131.62M | 31.79M | 56.24M | |
| Short-Term Investments | 71.26M | 70.87M | 89.00M | 178.61M | 93.14M | |
| Cash & Short-Term Investments | 285.03M | 300.21M | 220.62M | 210.40M | 149.38M | |
| Accounts Receivable | 9.90M | 2.59M | 11.00M | |||
| Other Receivables | 7.43M | 8.71M | 4.14M | 10.87M | 18.64M | |
| Receivables | 17.33M | 11.30M | 15.14M | 10.87M | 18.64M | |
| Inventory | 4.00M | 3.43M | ||||
| Prepaid Expenses | 7.85M | 5.20M | 5.93M | 4.42M | 4.31M | |
| Total Current Assets | 314.20M | 320.15M | 241.69M | 225.69M | 172.33M | |
| Property, Plant & Equipment | 12.26M | 12.86M | 7.53M | 9.15M | 10.77M | |
| Other Long-Term Assets | 2.45M | 2.37M | 1.55M | 567.00K | 106.00K | |
| Total Assets | 328.92M | 335.38M | 250.77M | 235.40M | 183.20M | |
| Accounts Payable | 8.04M | 8.27M | 4.88M | 9.11M | 4.82M | |
| Accrued Expenses | 25.08M | 27.06M | 26.50M | 12.14M | 9.13M | |
| Current Portion of Long-Term Debt | 16.23M | 13.57M | ||||
| Current Portion of Leases | 1.69M | 1.62M | 1.98M | 1.30M | 1.09M | |
| Current Unearned Revenue | 833.00K | 11.00M | ||||
| Other Current Liabilities | 8.94M | 6.84M | 806.00K | 253.00K | ||
| Total Current Liabilities | 60.82M | 57.35M | 45.17M | 22.81M | 15.03M | |
| Long-Term Debt | 255.98M | 258.29M | 105.88M | |||
| Long-Term Leases | 10.41M | 10.73M | 4.33M | 6.01M | 7.14M | |
| Long-Term Unearned Revenue | 21.36M | 11.71M | ||||
| Total Liabilities | 348.57M | 338.09M | 155.38M | 28.82M | 22.18M | |
| Common Stock | 51.00K | 51.00K | 50.00K | 42.00K | 34.00K | |
| Additional Paid-In Capital | 773.59M | 767.06M | 753.73M | 679.75M | 507.13M | |
| Retained Earnings | -786.18M | -762.69M | -653.17M | -469.73M | -343.08M | |
| Comprehensive Income & Other | -7.12M | -7.13M | -5.21M | -3.49M | -3.06M | |
| Shareholders' Equity | -19.65M | -2.71M | 95.39M | 206.58M | 161.03M | |
| Total Liabilities & Equity | 328.92M | 335.38M | 250.77M | 235.40M | 183.20M | |
| Total Debt | 284.31M | 284.21M | 112.19M | 7.32M | 8.23M | |
| Net Cash (Debt) | 718.00K | 16.01M | 108.43M | 203.08M | 141.14M | |
| Net Cash Per Share | 0.01 | 0.30 | 2.18 | 5.52 | 5.06 | |
| Filing Date Shares Outstanding | 53.24M | 51.22M | 49.95M | 42.74M | 34.23M | |
| Total Common Shares Outstanding | 51.24M | 50.90M | 49.76M | 42.52M | 34.17M | |
| Working Capital | 253.39M | 262.79M | 196.52M | 202.88M | 157.29M | |
| Book Value Per Share | -0.38 | -0.05 | 1.92 | 4.86 | 4.71 | |
| Tangible Book Value | -19.65M | -2.71M | 95.39M | 206.58M | 161.03M | |
| Tangible Book Value Per Share | -0.38 | -0.05 | 1.92 | 4.86 | 4.71 | |
| Machinery | 4.51M | 3.23M | 2.81M | 3.05M | ||
| Leasehold Improvements | 3.45M | 3.09M | 2.86M | 2.85M |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2025 | FY2024 | FYNone | FY2023 | |
|---|---|---|---|---|---|---|
| Net Income | -135.94M | -164.29M | -183.44M | -126.64M | -92.91M | |
| Depreciation & Amortization | 1.56M | 1.45M | 941.00K | 816.00K | 718.00K | |
| Asset Writedown & Restructuring Costs | 1.78M | 1.78M | ||||
| Loss (Gain) From Sale of Investments | -2.58M | -2.80M | -1.55M | -1.23M | 1.13M | |
| Stock-Based Compensation | 18.95M | 17.12M | 12.29M | 21.91M | 9.92M | |
| Other Operating Activities | 31.07M | 22.86M | 3.82M | 748.00K | -1.53M | |
| Change in Accounts Receivable | -11.21M | -3.89M | ||||
| Change in Inventory | -5.81M | -5.14M | ||||
| Change in Accounts Payable | 9.26M | 6.29M | -4.97M | 4.32M | 1.11M | |
| Change in Unearned Revenue | 11.68M | 964.50K | 10.56M | |||
| Change in Other Net Operating Assets | -8.08M | 3.21M | 9.45M | 10.85M | 6.31M | |
| Operating Cash Flow | -89.32M | -122.43M | -152.91M | -89.23M | -75.26M | |
| Capital Expenditures | -2.39M | -2.56M | -434.00K | -42.00K | -1.20M | |
| Sale (Purchase) of Intangibles | -128.50K | -283.50K | -495.00K | -401.00K | ||
| Investment in Securities | 33.37M | 30.87M | 91.95M | -84.28M | 42.61M | |
| Investing Cash Flow | 30.84M | 28.03M | 91.02M | -84.72M | 41.41M | |
| Total Debt Issued | 208.57M | 208.57M | ||||
| Net Debt Issued (Repaid) | 208.57M | 208.57M | ||||
| Issuance of Common Stock | 2.12M | 2.88M | 61.69M | 97.59M | 57.03M | |
| Other Financing Activities | 32.51M | 32.51M | 98.04M | 53.12M | 1.08M | |
| Financing Cash Flow | 243.20M | 243.96M | 159.73M | 150.71M | 58.12M | |
| Foreign Exchange Rate Adjustments | -6.67M | -2.75M | 2.64M | -1.21M | 1.24M | |
| Net Cash Flow | 178.06M | 146.81M | 100.48M | -24.45M | 25.51M | |
| Free Cash Flow | -91.71M | -124.99M | -153.34M | -89.27M | -76.46M | |
| Free Cash Flow Margin | -80.11% | -169.79% | ||||
| Free Cash Flow Per Share | -1.69 | -2.32 | -3.09 | -2.43 | -2.74 | |
| Levered Free Cash Flow | -92.91M | -50.27M | -52.01M | |||
| Unlevered Free Cash Flow | -89.29M | -50.27M | -52.01M | |||
| Change in Working Capital | -4.16M | 1.43M | 15.04M | 15.17M | 7.41M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2025 | FY2024 | FYNone | FY2023 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 1.44B | 816.32M | 684.58M | 478.84M | 500.35M | 291.47M |
| Enterprise Value | 1.44B | 789.74M | 538.08M | 410.70M | 432.21M | 128.26M |
| Last Close Price | 27.00 | 16.15 | 13.77 | 11.35 | 11.86 | 8.53 |
| PS Ratio | 12.56 | 11.09 | ||||
| PB Ratio | -301.12 | 7.18 | 2.32 | 1.81 | ||
| P/TBV Ratio | 7.18 | 2.32 | 1.81 | |||
| EV/Sales Ratio | 12.55 | 10.73 | ||||
| Debt / Equity Ratio | -14.47 | -104.83 | 1.18 | 0.04 | 0.05 | |
| Net Debt / Equity Ratio | 0.04 | 5.90 | -1.14 | -0.98 | -0.88 | |
| Net Debt / EBITDA Ratio | 0.01 | 0.10 | 0.58 | 1.45 | 1.28 | |
| Net Debt / FCF Ratio | 0.01 | 0.13 | 0.71 | 2.27 | 1.85 | |
| Quick Ratio | 4.97 | 5.43 | 5.22 | 9.70 | 11.18 | |
| Current Ratio | 5.17 | 5.58 | 5.35 | 9.90 | 11.46 | |
| Return on Equity (ROE) | -121.50% | -68.90% | -53.69% | |||
| Return on Assets (ROA) | -48.34% | -41.94% | -35.80% | |||
| Return on Capital Employed (ROCE) | -52.20% | -59.80% | -91.40% | -66.10% | -65.90% | |
| Earnings Yield | -9.46% | -20.12% | -26.80% | -26.45% | -31.88% | |
| FCF Yield | -6.38% | -15.31% | -22.40% | -18.64% | -26.23% | |
| Buyback Yield / Dilution | -9.26% | -8.49% | -34.98% | -13.96% |